Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area

Background In order to mitigate potential issues with antibiotic resistance in the treatment of patients with Helicobacter pylori infection, the selection of a therapeutic regimen is optimized by being aware of local eradication rates as well as the patient's medication history and previous diagnoses. Purpose This study primarily aimed to calculate the eradication rate of H. pylori infection in the New York Metropolitan area when using clarithromycin-based triple therapy per the dosing instructions for Omeclamox®-Pak. A secondary objective was to determine risk factors for therapeutic failure. Patients and methods A retrospective analysis was performed on 156 patients treated with clarithromycin-based triple therapy between 2011 and 2017 at a gastroenterology practice in Edison, New Jersey. Results The cumulative eradication rate for the intent-to-treat population was 84%, while the per-protocol rate was 86%. No differences were seen in the rates of subgroups defined by demographics or medication history. Conclusion Despite evidence and predictions from other sources in the last decade that clarithromycin-based treatments for H. pylori are becoming less effective, the results of this study support the use of clarithromycin-based triple therapy as a first-line treatment in the New York Metropolitan region.